Huadong Medicine’s innovative MUC-17 ADC HDM2012 completes dosing of first patient in Phase 1 clinical trial in China

CAR-T Digest - August 2020

06 August 2025: Huadong Medicine’s innovative MUC-17 ADC HDM2012 completes dosing of first patient in Phase 1 clinical trial in China

Huadong Medicine’s subsidiary, Sino-US Huadong, dosed the first patient in China in a Phase 1 trial of HDM2012, a novel MUC-17–targeting ADC for advanced solid tumors
HDM2012 is composed of an anti MUC-17 monoclonal antibody linked via a cleavable linker to a topoisomerase I inhibitor payload
Preclinical studies showed strong anti-tumor activity, favorable safety, and good druggability across multiple tumor models
The trial initiation follows NMPA approval in July 2025, aiming to accelerate clinical development and strengthen Huadong’s ADC oncology portfolio